Abstract
Aim To investigate whether children with various spinal muscular atrophy (SMA) subtypes treated with disease-modifying therapies (DMT) obtain neutral vertical (NV) head and trunk control, and how this relates to motor function.
Method In this observational cross-sectional study, a convenience sample of 21 children diagnosed with SMA (6y1m (4y), 10 female) was tested with Segmental Assessment of Trunk Control (SATCo) and functional assessments. A linear mixed-effects model (LME) was used for statistical analysis.
Results SATCo scores were measurably different between condition (types of SMA), F=4.96, p<.05, and control type (static, active, and reactive control), F=6.40, p<.05. The interaction condition*control type was also significant, F=3.14, p<.05. No child with SMA1 demonstrated NV head control and there was no relationship between SATCo scores and motor function. Four children with SMA2 and SMA3 demonstrated NV head static control, and one demonstrated NV mid-thoracic static control.
Interpretation The results indicate that children with SMA treated with DMTs acquire very little or no unsupported NV head/trunk control. SATCo was shown to be sensitive to differences in trunk control in different types of SMA revealing potential as an outcome measure for therapeutic interventions or treatment effectiveness. Further studies are needed to clarify this potential.
What this paper adds
Children with SMA1 treated with DMTs do not attain upright head control
Some children with SMA2/SMA3 treated with DMTs attain upright head/trunk control
Differences in caudal extent of head/trunk control were found between SMA types
SATCo is more efficient in identifying upright head/trunk control than functional tests
Postural control assessment using SATCo has the potential to track treatment outcomes
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Medical Research Council (MRC) (MR/T002034/1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The London-Brent Research Ethics Committee gave ethical approval for this work (IRAS project ID: 233469).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data that support the findings of this study will be available on request from the corresponding author in the near future. The data are not publicly available due to privacy or ethical restrictions.
Abbreviations
- CHOP-INTEND
- CHOP-I The Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders
- HINE
- Hammersmith Infant Neurological Examination
- LME
- Linear mixed-effects model
- NV NVP
- Neutral vertical, neutral vertical posture
- OA
- Onasemnogene abeparvovec
- RHS
- Revised Hammersmith Scale
- SATCo
- Segmental Assessment of Trunk Control
- SMA
- Spinal muscular atrophy
- SMA0, SMA1, SMA2, SMA3, SMA4
- Spinal muscular atrophy types 0, 1, 2, 3, and 4
- SMN
- Survival motor neuron
- WHO
- World Health Organization
